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ABSTRACT 
 
We evaluated the efficacy and safety of Ciprofloxacin Dry Powder for Inhalation (DPI) 
in patients with non-cystic fibrosis bronchiectasis (NCFB), ≥2 exacerbations in the 
previous year, and predefined sputum bacteria. 
Patients were randomised 2:1 to twice-daily Ciprofloxacin DPI 32.5 mg or placebo in 
14-day or 28-day on/off treatment cycles for 48 weeks. Primary end-points were time 
to first exacerbation and frequency of exacerbations. Enrolling countries and alpha 
level split (0.049 and 0.001 for 14-day and 28-day cycles, respectively) differed from 
RESPIRE 1.  
Patients were randomised to Ciprofloxacin DPI 14-days on/off (n=176), 28-days 
on/off (n=171) or placebo 14-days on/off (n=88), 28-days on/off (n=86). The 
exacerbation rate was low across treatment arms (mean [SD] 0.6 [0.9]). Active 
treatment showed trends to prolonged time to first exacerbation (Ciprofloxacin DPI 
14-days on/off: hazard ratio 0.87 [95.1% CI 0.62–1.21], p=0.3965; Ciprofloxacin DPI 
28-days on/off: 0.71 [99.9% CI 0.39–1.27]; p=0.0511) and reduced frequency of 
exacerbations (Ciprofloxacin DPI 14-days on/off incidence rate ratio 0.83 [95.1% CI 
0.59–1.17], p=0.2862; Ciprofloxacin DPI 28-days on/off 0.55 [99.9% CI 0.30–1.02]; 
p=0.0014), although neither achieved statistical significance. Ciprofloxacin DPI was 
well tolerated. 
Trends towards clinical benefit were seen with Ciprofloxacin DPI but primary end-
points were not met.  
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Introduction 
 
Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease with a range 
of underlying aetiologies across geographical regions [1] and a variable clinical 
course. Patients with NCFB are subject to a vicious cycle of inflammation, poor 
mucus clearance and recurrent infection [2; 3]. This cycle manifests as a chronic 
cough, sputum production, airway damage and exacerbations – the severity and 
impact of each exacerbations varying from patient to patient – and is responsible for 
progressive lung damage [2; 4].  
Exacerbations of bronchiectasis are characterised by a debilitating increase in 
symptoms [5] and are associated with poorer health outcomes, including reduced 
quality of life, depression, anxiety [6], and increased mortality [7]. Reducing the 
frequency of exacerbations is therefore an important treatment goal; however, there 
are currently no antibiotic therapies licensed for this.  
The RESPIRE programme consisted of two trials of the same overall design, as 
required by regulatory agencies. The objective of both studies was to assess the 
efficacy and safety of 14- and 28-days on/off regimens of Ciprofloxacin Dry Powder 
for Inhalation (DPI) in prolonging the time to first exacerbation and reducing the 
frequency of exacerbations in patients with NCFB. The RESPIRE 1 trial 
demonstrated that treatment with a 14-day on/off cycle of Ciprofloxacin DPI 
significantly reduced the frequency of exacerbations and prolonged time to first 
exacerbation in patients with NCFB. The 28-day Ciprofloxacin DPI arm of RESPIRE 
1 had trends towards clinical benefit but failed to reach statistical significance [8]. 
This paper reports the results of the phase III RESPIRE 2 trial (NCT02106832). The 
main difference between RESPIRE 1 and 2 were a change in the recruiting countries 
(RESPIRE 2 drew more patients from Asia and Eastern Europe than RESPIRE 1) 
and specific alterations to the statistical plan, as described in the following sections.   
Methods 
Study design and treatment 
The RESPIRE trials had the same overall methodology, which has been reported 
previously [9]. Two interventions were studied over 48 weeks: Ciprofloxacin DPI 32.5 
mg twice-daily 14-days on/off (12 cycles) and Ciprofloxacin DPI 28-days on/off (6 
cycles). There was an 8-week off-treatment follow-up period.  
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Study population  
Patients with a primary diagnosis of NCFB (idiopathic or post-infectious aetiology) 
and stable disease were enrolled. Key inclusion criteria were: at least two 
exacerbations in the previous 12 months and a positive sputum culture at screening 
for at least one of seven pre-specified pathogens (Pseudomonas aeruginosa, 
Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, 
Streptococcus pneumoniae, Stenotrophomonas maltophilia, or Burkholderia 
cepacia). Patients with active allergic bronchopulmonary aspergillosis, active or 
actively treated non-tuberculous mycobacterial lung infection or tuberculosis, a 
primary diagnosis of chronic obstructive pulmonary disease (COPD), or documented 
chronic asthma were excluded. Randomisation was stratified by geographical region, 
pre-therapy positive culture for P. aeruginosa and chronic macrolide use. 
End-points 
Two different hierarchical statistical analysis approaches were developed with 
different regulatory authorities. The primary end-point for the United States Food and 
Drug Administration (FDA) was time to first exacerbation within 48 weeks after start 
of treatment (Ciprofloxacin DPI versus pooled placebo). For the European Medicines 
Agency and other agencies (EMA/others), such as the China State Drug 
Administration, the primary end-point was frequency of exacerbations during the 48-
week study (Ciprofloxacin DPI versus matching placebo). The pooled placebo groups 
refers to all patients from the 14- and 28-day on/off placebo arms; matching placebo  
refers to Ciprofloxacin DPI 14 days on/off compared with placebo 14 days on/off, and 
Ciprofloxacin DPI 28 days on/off compared with placebo 28 days on/off [4]. For 
primary end-points, exacerbations had to meet three criteria: worsening of at least 
three signs or symptoms (dyspnoea, wheezing, cough, 24-hour sputum volume, or 
sputum purulence) for at least 2 consecutive days (beyond normal day-to-day 
variations); fever (body temperature >38.0°C) or malaise/fatigue; and treatment with 
systemic antibiotic(s). Pre-defined subgroups and safety end-points are described in 
the supplementary material (online supplementary sections 1 and 2). Secondary end-
points have been detailed previously [8; 9]. A secondary end-point of particular 
interest was exacerbation rate according to a less stringent definition, i.e. a 
respiratory event with worsening of at least one of the abovementioned 
sign/symptoms and systemic antibiotic use.  
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Analyses 
The statistical analysis plan for the RESPIRE programme has been described 
previously [9]. RESPIRE 2 followed the same analysis plan as for RESPIRE 1 with 
two exceptions. First, the primary analysis models for the frequency of exacerbation 
end-point were harmonised between the FDA and EMA/others analyses with respect 
to handling of treatment discontinuations. In the RESPIRE 1 FDA analysis, the 
frequency of exacerbations was extrapolated for patients not completing the 48-week 
period, whereas in RESPIRE 2 the patients’ time in study was included as an offset 
variable in the FDA analysis as for the EMA/others analysis. Second, the significance 
levels (alpha level split) were amended before study end, based on experience 
gained from RESPIRE 1. In RESPIRE 1, a Bonferroni correction was used, resulting 
in a significance level of 0.025 for each treatment arm (14-days on/off and 28-days 
on/off). Following the statistical failure of the Ciprofloxacin DPI 28-days on/off arm in 
RESPIRE 1, the alpha correction for RESPIRE 2 was prospectively amended to a 
weighted Bonferroni correction of 0.049 for the 14-days on/off arm and 0.001 for the 
28-days on/off arm. The sponsoring company discussed this change before study 
end with the regulatory agencies who approved this change. Further details are given 
in online supplementary section S3. 
 
Results 
Patients 
A total of 521 patients from 24 countries were randomised to treatment (figure 1); the 
first patient visit was in April 2014 and the last visit was in October 2016 . The highest 
enrolling countries were Russia (11.5%), Bulgaria (10.4%), and Latvia (8.6%) (online 
supplementary table S1).  
Patient demographics and baseline characteristics were balanced across groups 
(table 1). The majority of patients (58.0%) were female, the mean age was 
approximately 60 years, and patients had a high likelihood of P. aeruginosa infection 
(60.7% of patients; see online supplementary table S2 for additional pre-specified 
baseline pathogens). Lung function was generally poor, with over 40% of patients 
having an forced expiratory volume in 1 second (FEV1) predicted of <50%. 
Approximately 30% of patients had a medical history of COPD, and use of 
concomitant respiratory medications considered part of NCFB therapy was common 
(online supplementary table S3). 
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A total of 442 patients (84.8%) completed the study and 79.5% of patients 
(n=414/521) completed treatment. Patient compliance was high (mean >95% in all 
arms) (table 2). 
 
Primary end-points 
Both the 14- and 28-days Ciprofloxacin DPI on/off arms increased the time to first 
exacerbation versus pooled placebo (figure 2). However, neither Ciprofloxacin DPI 
treatment arm demonstrated a statistically significant difference compared with 
pooled placebo (Ciprofloxacin DPI 14-days on/off hazard ratio [HR]=0.87 [95.1% 
confidence interval (CI) 0.62–1.21]; p=0.3965 and Ciprofloxacin DPI 28-days on/off 
HR=0.71 [99.9% CI 0.39–1.27]; p=0.0511; table 3). The median time to first 
exacerbation was not estimable for any treatment arm due to the low exacerbation 
rates. Overall, 61.4% and 67.3% of patients treated with Ciprofloxacin DPI 14-days 
on/off and 28 days on/off, respectively, did not experience an exacerbation matching 
the stringent definition, compared with 58.0% of patients in the pooled placebo arm. 
Ciprofloxacin DPI 14-days on/off reduced the exacerbation incidence rate by 17% 
over 48 weeks (incidence rate ratio [IRR]=0.83 [95.1% CI 0.59–1.17]; p=0.2862), 
while the Ciprofloxacin DPI 28-days on/off regimen reduced the exacerbation 
incidence rate by 45% (IRR=0.55 [99.9% CI 0.30–1.02]; p=0.0014; table 3). Neither 
arm reached the predefined statistical significance level (p=0.049 for the 14-day 
regimen and 0.001 for the 28-day regimen). Overall, the frequency of exacerbations 
in all arms was very low (figure 3). The overall mean (standard deviation [SD]) 
number of exacerbations was 0.6 (0.9). Equivalent data for the treatment arms were 
0.6 (0.8) in the Ciprofloxacin DPI 14-days on/off arm compared with 0.7 (1.0) in the 
matching placebo arm, and 0.4 (0.6) in the Ciprofloxacin DPI 28-days on/off arm 
versus 0.7 (1.1) in the matching placebo arm.  
Over 48 weeks, 61.4% of patients treated with Ciprofloxacin DPI 14-days on/off 
compared with 67.3% of patients treated with Ciprofloxacin DPI 28-days on/off and 
58.0% of patients in the pooled placebo arm did not experience a protocol-defined 
exacerbation for the primary end-point.  
 
Subgroup analyses 
Exploratory analyses of the primary end-point in pre-specified subgroups did not 
reveal any differences in any of the subgroups for time to first exacerbation or 
frequency of exacerbation (online supplementary figure S1).  
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Secondary end-points  
Due to the hierarchical nature of the statistical analysis plan, formal significance 
testing could not be performed for secondary end-points because the primary end-
points were not met. Exploratory analyses of secondary end-points suggested that 
Ciprofloxacin DPI treatment was associated with benefits, including a reduced 
frequency of exacerbations (defined according to the primary end-point) versus 
pooled placebo for the Ciprofloxacin DPI 28-days on/off arm (figure 4).  
The mean (SD) number of exacerbations reported using the less stringent definition 
was 0.7 (1.0) for Ciprofloxacin DPI 14-days on/off compared with 0.8 (1.1) in the 
matching placebo arm, and 0.5 (0.8) for Ciprofloxacin DPI 28-days on/off compared 
with 0.9 (1.1) in the matching placebo arm.  
Safety 
Ciprofloxacin DPI was well tolerated, with lowest adverse event rates observed in the 
Ciprofloxacin DPI 28-days on/off arm. A total of 349/519 (67.2%) patients 
experienced an adverse event at any time after enrolment: 131 (75.3%) patients in 
the Ciprofloxacin DPI 14-days on/off arm, 101 (59.1%) in the Ciprofloxacin DPI 28-
days on/off arm, and 117 (67.2%) in the pooled placebo group.  
Overall, 64.9% of patients experienced a treatment-emergent adverse event (TE-
AE). Treatment emergent musculoskeletal adverse events were infrequently 
reported. Tendon disorders were reported by 2 patients in each Ciprofloxacin DPI 
treatment group (1 tendon disorder and 1 trigger finger in the Ciprofloxacin DPI 14-
days on/off group; 1 tendon discomfort and 1 ligament sprain in the Ciprofloxacin DPI 
28-days on/off group) and 0 patients in the placebo groups. Premature 
discontinuations due to TE-AEs were uncommon and occurred with similar 
frequencies across treatment arms (table 4).  
Serious TE-AEs occurred in 22.0% of patients overall; rates were slightly lower in the 
Ciprofloxacin DPI 28-days on/off arm compared with other arms. Respiratory 
disorders, and infections and infestations were the most common system organ 
classes reported for serious TE-AEs (online supplementary table S4). One serious 
TE-AE (atrial flutter) was considered drug related. This TE-AE occurred in a subject 
in the Ciprofloxacin DPI 28-days on/off group who had a history of ischaemic heart 
disease. This patient also experienced severe fatal congestive cardiomyopathy, 
which was reported in parallel but was not considered to be drug related. 
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Nine treatment-emergent deaths were reported during the study (3 [1.7%] in the 
Ciprofloxacin DPI 14-days on/off arm, 4 [2.3%] in the Ciprofloxacin DPI 28-days 
on/off arm, and 2 [1.1%] in the pooled placebo group), but no fatalities were 
considered to be drug related and deaths were consistent with morbidities common 
to the patient population being studied (online supplementary table S4).  
Changes in ciprofloxacin minimal inhibitory concentrations 
At baseline, 98/521 (18.8%) patients had a pathogen with an elevated minimal 
inhibitory concentration (MIC) for ciprofloxacin (defined as resistant based on 
systemic ciprofloxacin breakpoints as specified in online supplementary section S2) 
isolated from their sputum. During the study, elevated MICs were more common in 
patients receiving active therapy. The percentage of patients with at least one isolate 
from sputum with an elevated MIC at any time point from baseline to end of study 
was 52.3% for Ciprofloxacin DPI 14-days on/off, 39.8% for Ciprofloxacin DPI 28-days 
on/off, and 29.5% for pooled placebo. At the end of study visit that occurred 8 weeks 
after the end of treatment, pathogens with elevated MICs were isolated from 26 
patients (5%) (Ciprofloxacin DPI 14-days on/off n=12/176 [6.8%]; Ciprofloxacin DPI 
28-days on/off n=10/171 [5.8%]; pooled placebo n=4/174 [2.3%]) who had 
susceptible bacteria at baseline.  
Discussion 
The RESPIRE 2 trial constitutes the second trial in the RESPIRE programme. 
RESPIRE 1 demonstrated a significant treatment effect for the Ciprofloxacin DPI 14-
days on/off treatment regimen and a trend towards improved outcomes in the 
Ciprofloxacin DPI 28-days on/off arm [8]. In RESPIRE 2, end-points favoured 
Ciprofloxacin DPI over placebo, but the positive efficacy signals did not translate into 
statistical significance for either active treatment arm. The observed positive trends in 
RESPIRE 2 were generally more pronounced in the Ciprofloxacin DPI 28-days on/off 
group than in the 14-days on/off group. However, due to the pre-specified 
significance level of 0.001 for the Ciprofloxacin DPI 28-days on/off arm, differences 
from placebo did not achieve statistical significance.  
Exacerbation rates in RESPIRE 2 were much lower than expected and lower than 
those observed in RESPIRE 1. In RESPIRE 2, 62.2% of patients did not experience 
an exacerbation according to the primary definition (defined by three signs or 
symptoms), which was notably higher than the 52% of patients in RESPIRE 1 with no 
exacerbations [8]. As the study entry criteria were chosen to enrich the population of 
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‘frequent exacerbators’, requiring ≥2 documented exacerbations in the previous year, 
the low exacerbation rates that occurred during the trial were unexpected. For both 
trials, a stringent definition of exacerbation was used for primary end-point 
evaluations [9]. This definition was not, however, applied for the entry criteria. As 
each patient experiences their disease differently [10], and as patients are often 
educated to take antibiotic treatment when symptoms increase, it is likely that the 
prior exacerbations did not meet the stringent definition used during the trial. A 
proposed standardised definition of an exacerbation has recently been published 
[11]; this may be of benefit in future clinical trials to reduce heterogeneity.  
Understanding the low exacerbation rates observed in both active and placebo arms 
of RESPIRE 2 and the differences in exacerbation rates between RESPIRE 1 and 2, 
requires examination of a number of factors, including patient characteristics and 
geography. Baseline demographics varied somewhat between RESPIRE 1 and 
RESPIRE 2, despite their identical inclusion and exclusion criteria. As patient 
phenotype is known to affect prognosis [10], it is possible that the differing patient 
profiles led to different clinical outcomes. Patients in RESPIRE 2 were generally 
younger (mean age of 60.1 versus 64.7 years) and more likely to have had only two 
exacerbations in the last year (78% versus 55%), than patients in RESPIRE 1 [8]; 
two episodes was the minimum frequency of exacerbations required to enter the 
study. RESPIRE 2 patients had poorer lung function as indicated by the proportion of 
patients with FEV1 predicted <50% (41.8% versus 30.0%) and more respiratory 
symptoms as assessed by the St. George’s Respiratory Questionnaire symptom 
component score (mean of 61.0 versus 56.8) [8].  
Although a primary diagnosis of COPD was an exclusion criterion, 28% of patients in 
RESPIRE 2 had a history of COPD versus 16% in RESPIRE 1, suggesting that more 
patients in RESPIRE 2 had an overlapping diagnosis of bronchiectasis/COPD. This is 
supported by the greater theophylline use in RESPIRE 2 (8.1%) versus RESPIRE 1 
(2.2%). The precise nature of the relationship between COPD and bronchiectasis 
remains to be established. Optimal treatment of these patients is poorly understood 
and may differ from therapies recommended for either condition alone [12]. Excluding 
patients with an overlapping bronchiectasis/COPD diagnosis may result in more 
homogeneous NCFB patient populations in clinical trials. Patients in RESPIRE 2 had 
indicators of more-severe airflow obstruction, but bronchiectasis severity could not be 
fully evaluated because computed tomography scans were not assessed at baseline. 
Not all parameters included in bronchiectasis severity indices were collected at 
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baseline, as details for these had not been published when the RESPIRE studies 
were being designed [7; 13].   
RESPIRE 1 and RESPIRE 2 also differed in the geographical regions that were 
represented, with RESPIRE 2 enrolling more patients from Asia and Eastern Europe. 
The variability in clinical practice could have potentially impacted the determination of 
exacerbations and treatment prior to enrolment. Specialist care for individuals with 
bronchiectasis is well developed, and research interest is relatively intense in 
Western Europe, the US and Australia, which has led to the development of 
treatment guidelines and national standards [14;15; 16]. European guidelines have 
only recently been published [17], and similar initiatives have been less common in 
other areas of the world [1]. This may have led to different disease management 
practices prior to enrolment. For example, patients in RESPIRE 2 were less likely to 
be treated with standard respiratory medications (67.9% versus 80.5%, respectively) 
or long-term macrolide treatment (7.7% versus 15.9%) than those in RESPIRE 1 [8]. 
This might reflect individual country practices, or could be explained by different 
patient phenotypes. Reducing the heterogeneity of patient populations, in terms of 
phenotypic differences and standards of care prior to enrolment, is an important 
consideration for future trials.  
Any comparison of the outcomes of RESPIRE 1 and 2 should take into consideration 
the change in extrapolation method and significance levels. Based on experience 
gained in RESPIRE 1, significance levels were amended by the sponsor with 
agreement from regulatory authorities to maximise the likelihood of achieving a 
significant result in the Ciprofloxacin DPI 14-days on/off arm. If the alpha adjustment 
applied in RESPIRE 1 (p=0.025) had been used in RESPIRE 2, the Ciprofloxacin 
DPI 28-days on/off arm would have met the primary end-point for the EMA/others 
analysis of frequency of exacerbations (IRR=0.55 [99.9% CI 0.30–1.02]; p=0.0014). 
The FDA primary end-point, however, would not have been statistically significant, 
nor would results in the Ciprofloxacin DPI 14-days on/off arm have been affected.  
As observed in RESPIRE 1, Ciprofloxacin DPI was well tolerated. The number of 
study-drug-related TE-AEs was markedly lower in RESPIRE 2 than RESPIRE 1 
(13.7% versus 25.1%) [8]. Differences were largely due to lower numbers of 
respiratory TE-AEs; contributory factors may include a lower rate of exacerbations in 
RESPIRE 2 or a higher threshold for diagnosis of these adverse events in centres 
involved in RESPIRE 2 versus RESPIRE 1. Trial discontinuation rates were low (5% 
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due to TE-AEs) and comparable across treatment arms. Together with data from 
RESPIRE 1, these findings support a favourable safety profile for Ciprofloxacin DPI. 
The limitations of the RESPIRE programme study design have been discussed 
previously [8]. RESPIRE 2 additionally highlighted the impact of low exacerbation 
rates on efficacy outcomes. Future NCFB trials should consider using a more 
stringent definition for prior exacerbations as an inclusion criterion and collecting data 
needed to calculate bronchiectasis severity based on published severity assessment 
tools [7; 13].  
In summary, despite efficacy signals showing trends towards clinical benefits and 
excellent tolerability in the RESPIRE 2 study, neither the 14- or 28-days on/off 
Ciprofloxacin DPI arms met the primary end-points of increasing time to first 
exacerbation or reducing frequency of exacerbations. The RESPIRE clinical trial 
programme thus encapsulates both the promise and difficulties of documenting a 
statistically significant impact on exacerbations in NCFB patients, and substantially 
contributes to the body of knowledge on the optimal design of clinical trials.  
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Tables and Figures 
 
TABLE 1 Patient demographics and baseline characteristics  
 
 Ciprofloxacin DPI 
14-days on/off 
N=176 
Placebo 14-
days on/off 
 
N=88 
Ciprofloxacin DPI 
28-days on/off 
N=171 
Placebo 28-
days on/off 
 
N=86 
Pooled 
placebo 
 
N=174 
Total 
N=521 
Female, n (%) 96 (54.5) 62 (70.5) 92 (53.8) 52 (60.5) 114 (65.5) 302 (58.0) 
Age, years 60.4 (13.7) 60.4 (15.0) 59.3 (14.2) 60.6 (13.7) 60.5 (14.3) 60.1 (14.0) 
Idiopathic 
aetiology, n (%) 
62 (35.2) 32 (36.4) 43 (25.1) 36 (41.9) 68 (39.1) 173 (33.2) 
Region#, n (%)       
Europe 1 64 (36.4) 32 (36.4) 65 (38.0) 32 (37.2) 64 (36.8) 193 (37.0)  
Europe 2 54 (30.7) 27 (30.7) 54 (31.6) 28 (32.6) 55 (31.6) 163 (31.3) 
Africa 0 0 2 (1.2) 0 2 (1.1) 2 (0.4) 
Latin America 6 (3.4) 3 (3.4) 7 (4.1) 2 (2.3) 5 (2.9) 18 (3.5) 
Asia 39 (22.2) 19 (21.6) 33 (19.3) 17 (19.8) 36 (20.7) 108 (20.7) 
Australia 8 (4.5) 4 (4.5) 5 (2.9) 4 (4.7) 8 (4.6) 21 (4.0) 
United States 5 (2.8) 3 (3.4) 5 (2.9) 3 (3.5) 6 (3.4) 16 (3.1) 
Ethnicity       
White 133 (75.6) 68 (77.3)  135 (78.9) 67 (77.9) 135 (77.6) 403 (77.4) 
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 Ciprofloxacin DPI 
14-days on/off 
N=176 
Placebo 14-
days on/off 
 
N=88 
Ciprofloxacin DPI 
28-days on/off 
N=171 
Placebo 28-
days on/off 
 
N=86 
Pooled 
placebo 
 
N=174 
Total 
N=521 
Black/ African 2 (1.1) 1 (1.1)  2 (1.2) 0 1 (0.6) 5 (1.0) 
Asian 41 (23.3) 18 (20.5)  33 (19.3) 19 (22.1) 37 (21.3) 111 (21.3) 
Multiple 0 1 (1.1)  1 (0.6) 0 1 (0.6) 2 (0.4) 
FEV1 % predicted  54.3 (17.3) 55.8 (18.6) 56.4 (18.8) 56.2 (18.2) n/c 55.5 (18.2) 
FEV1 <50% 
predicted, n (%) 
78 (44.3) 39 (44.3) 65 (38.0) 36 (41.9) 75 (43.1) 218 (41.8) 
SGRQ symptoms 
component score†  
61.26 (19.54) 63.47 (19.48) 60.75 (20.61) 58.56 (19.17) n/c 61.0 (19.82) 
QOL-B RSS† 52.17 (18.49) 48.67 (17.72) 50.14 (19.07) 53.95 (16.00) n/c 51.2 (18.6) 
Number of 
exacerbations in 
prior 12 months 
2.4 (0.8) 2.4 (0.7) 2.3 (0.7) 2.3 (1.0) 2.4 (0.9) 2.4 (0.8) 
>2 exacerbations in 
prior 12 months, n 
(%) 
42 (23.9) 22 (25.0) 35 (20.5) 16 (18.6) 38 (21.8) 115 (22.1) 
Hospitalised for 
exacerbation in 
prior year, n (%) 
80 (45.5) 39 (44.3) 65 (38.0) 35 (40.7) 74 (42.5) 219 (42.0) 
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 Ciprofloxacin DPI 
14-days on/off 
N=176 
Placebo 14-
days on/off 
 
N=88 
Ciprofloxacin DPI 
28-days on/off 
N=171 
Placebo 28-
days on/off 
 
N=86 
Pooled 
placebo 
 
N=174 
Total 
N=521 
Long-term oral 
macrolides, n (%) 
11 (6.3) 7 (8.0) 14 (8.2) 8 (9.3) 15 (8.6) 40 (7.7) 
History of COPD, n 
(%) 
50 (28.4) 31 (35.2) 39 (22.8) 28 (32.6) 59 (33.9) 148 (28.4) 
Baseline P. 
aeruginosa‡, n (%) 
107 (60.8) 55 (62.5) 99 (58.2) 54 (63.5) 109 (63.0) 315 (60.7) 
Data are presented as mean (standard deviation) unless otherwise indicated. COPD: chronic obstructive pulmonary disease; DPI: dry powder 
for inhalation; FEV1: forced expiratory volume in 1 second; n/c: not calculated; QOL-B RSS: Quality of Life-Bronchiectasis Respiratory 
Symptoms Domain Score; SD: standard deviation; SGRQ: St George’s Respiratory Questionnaire. #: Europe 1: Austria, Czech Republic, 
Germany, Latvia, Lithuania, the Netherlands, Poland, Russia; Europe 2: Bulgaria, Portugal, Romania, Serbia, Turkey; Asia: China, Hong Kong, 
Philippines, South Korea, Taiwan, Thailand; Latin America: Argentina and Brazil; Africa: South Africa. †: Not available for Latvia, Philippines, 
Portugal, Romania, Serbia, Thailand, Turkey (177 subjects [34%] of RESPIRE 2 population) due to the lack of a translated version. ‡: Patients 
could have more than one species isolated. 
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TABLE 2 Treatment compliance and duration# 
 
 
Ciprofloxacin 
DPI 
14-days on/off 
N=176 
Placebo 
14-days on/off 
 
N=88 
Ciprofloxacin 
DPI 
28-days on/off 
N=171 
Placebo 
28-days on/off 
 
N=86 
Compliance     
Mean, % (SD) 96.2 (8.2) 96.2 (9.9) 95.8 (10.8) 96.3 (8.9) 
Compliance ≥80%,  
n (%) 
167 (94.9) 82 (93.2) 159 (93.0) 81 (94.2) 
Treatment duration     
Mean (SD) duration, 
days 
281.7 (91.6) 272.1 (103.0) 269.5 (86.4) 262.7 (90.7) 
Median (SD) 
duration, days 
322.0 322.0 308.0 307.0 
DPI: dry powder for inhalation; SD: standard deviation.#:Compliance was determined 
after imputation of (partially) missing exposure dates as number of capsules 
taken/number of planned capsules. Treatment duration was assessed from first to 
last day of study drug intake irrespective of interruptions or off-cycles; the final off-
cycle after the last dose was not included. The maximum treatment duration was 322 
days for the 14-days on/off treatment arm and 308 days for the 28-days on/off 
treatment arm
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TABLE 3 Primary end-points: time to first exacerbation and frequency of exacerbation# in 
patients treated with Ciprofloxacin DPI versus placebo over 48 weeks. 
Primary end-point HR or IRR† 
 
Confidence 
interval‡ 
p-value 
(Wald-type test) 
 Time to first exacerbation 
Ciprofloxacin DPI 14-days 
on/off versus pooled placebo 
0.8662 0.62–1.21 0.3965 
Ciprofloxacin DPI 28-days 
on/off versus pooled placebo 
0.7062 0.39–1.27 0.0511 
 Frequency of exacerbation 
Ciprofloxacin DPI 14-days 
on/off versus matching 
placebo 
0.8313 0.59–1.17 0.2862 
Ciprofloxacin DPI 28-days 
on/off versus matching 
placebo 
0.5493 0.30–1.02 0.0014 
#: for the primary end-points, an exacerbation (stringent definition) was defined as a respiratory 
event requiring systemic antibiotic use AND presence of fever (>38.0°C) or malaise/fatigue 
AND worsening of at least three of five signs/symptoms (dyspnoea, wheezing, cough, 24-hour 
sputum volume or sputum purulence); †: hazard ratios (HR) were calculated for time to first 
exacerbation; incidence rate ratios (IRRs) were calculated for frequency of exacerbation; ‡: the 
confidence interval is 95.1% for comparisons of Ciprofloxacin DPI 14-days on/off versus 
placebo and 99.9% for comparisons of Ciprofloxacin DPI 28-days on/off versus placebo.  
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TABLE 4 Treatment-emergent adverse events (MedDRA classifications).  
Number (%) of patients Ciprofloxacin DPI Pooled 
placebo 
n=174 
Total  
N=519# 14 days on/off 
n=174# 
28 days on/off 
n=171 
Any TE adverse event 127 (73.0) 94 (55.0) 116 (66.7) 337 (64.9) 
Any drug-related TE adverse 
event  
28 (16.1) 19 (11.1) 24 (13.8) 71 (13.7) 
TE adverse event with outcome 
death 
3 (1.7) 4 (2.3) 2 (1.1) 9 (1.7) 
Discontinuation due to TE 
adverse event 
10 (5.7) 6 (3.5) 10 (5.7) 26 (5.0) 
Any serious TE adverse event 45 (25.9) 28 (16.4) 41 (23.6) 114 (22.0) 
Any drug-related serious TE 
adverse event 
0 1 (0.6) 0 1 (0.2) 
TE adverse event reported in at least 5% of patients in any group  
Respiratory, thoracic and 
mediastinal disorders 
70 (40.2) 42 (24.6) 68 (39.1) 180 (34.7) 
Bronchiectasis 24 (13.8) 17 (9.9) 21 (12.1) 62 (11.9) 
Haemoptysis 17 (9.8) 12 (7.0) 22 (12.6) 51 (9.8) 
Cough 7 (4.0) 5 (2.9) 11 (6.3) 23 (4.4) 
Bronchospasm 7 (4.0) 3 (1.8) 9 (5.2) 19 (3.7) 
Dyspnoea 10 (5.7) 4 (2.3) 3 (1.7) 17 (3.3) 
Infections and infestations 49 (28.2) 45 (26.3) 43 (24.7) 137 (26.4) 
Nasopharyngitis 16 (9.2) 10 (5.8) 14 (8.0) 40 (7.7) 
Upper respiratory tract 
infections 
8 (4.6) 10 (5.8) 5 (2.9) 23 (4.4) 
Gastrointestinal disorders 29 (16.7) 22 (12.9) 26 (14.9) 77 (14.8) 
Nervous system disorders 25 (14.4) 26 (15.2) 12 (6.9) 63 (12.1) 
Headache 10 (5.7) 10 (5.8) 5 (2.9) 25 (4.8) 
Dysgeusia 8 (4.6) 9 (5.3) 2 (1.1) 19 (3.7) 
General disorders and 
administration site conditions 
14 (8.0) 14 (8.2) 13 (7.5) 41 (7.9) 
Musculoskeletal and connective 
tissue disorders 
18 (10.3) 12 (7.0) 10 (5.7) 40 (7.7) 
Skin and subcutaneous tissue 
disorders 
12 (6.9) 8 (4.7) 11 (6.3) 31 (6.0) 
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Number (%) of patients Ciprofloxacin DPI Pooled 
placebo 
n=174 
Total  
N=519# 14 days on/off 
n=174# 
28 days on/off 
n=171 
Investigations 13 (7.5) 6 (3.5) 10 (5.7) 29 (5.6) 
Metabolism and nutrition 
disorders 
11 (6.3) 5 (2.9) 8 (4.6) 24 (4.6) 
Vascular disorders 9 (5.2) 5 (2.9) 6 (3.4) 20 (3.9) 
#: two randomised subjects did not receive study medication (both in Ciprofloxacin 
DPI 14-days on/off).  
Treatment-emergent adverse events were defined as those that first occurred or 
worsened during the study from the first administration of study medication 
(Ciprofloxacin DPI or placebo) through 30 days after administration of the last dose of 
study medication.  
DPI: dry powder for inhalation; MedDRA: Medical Dictionary for Regulatory Activities; 
TE: treatment-emergent 
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FIGURE 1 Patient disposition. 
 
 
DPI: dry powder for inhalation; EOS: end of study. #: randomisation stratified by 
geographical region, pre-therapy positive culture for P. aeruginosa, and chronic 
macrolide use; †: patients randomised who received at least one treatment dose; ¶: 
patients with EOS data available include those who completed treatment and 
subsequent follow-up, or prematurely discontinued treatment but were followed 
further until the planned end of study (52/54 weeks), or prematurely discontinued 
treatment but completed the planned 8 weeks of follow-up. 
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FIGURE 2 Time to first exacerbation: a) patients receiving Ciprofloxacin DPI 14-
days on/off or placebo, b) patients receiving Ciprofloxacin DPI 28-days on/off or 
placebo.  
 
 
   
 
 
 
For the primary end-point exacerbations were required to meet three criteria: (1) 
worsening in at least three signs/ or symptoms (dyspnoea, wheezing, cough, sputum 
volume, or sputum purulence); (2) fever (body temperature >38.0°C) OR 
malaise/fatigue; and (3) systemic antibiotic treatment.  
a) 
b) 
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FIGURE 3 Descriptive frequency of exacerbation over 48 weeks: a) for patients 
receiving Ciprofloxacin DPI 14-days on/off or matching placebo, b) patients receiving 
Ciprofloxacin DPI 28-days on/off or matching placebo.  
 
 
 
Numbers within or above bars indicate number of patients.  
For the primary end-point exacerbations were required to meet three criteria: (1) 
worsening in at least three signs/or symptoms (dyspnoea, wheezing, cough, sputum 
volume, or sputum purulence); (2) fever (body temperature >38.0°C) OR 
malaise/fatigue; and (3) systemic antibiotic treatment. 
DPI: dry powder for inhalation. 
 Page 24 of 25 
FIGURE 4 Results for Ciprofloxacin DPI in FDA and EMA/others hierarchical analyses for a) Ciprofloxacin DPI 14-days on/off and b) 
Ciprofloxacin 28-days on/off vs matched placebo (MPL) or pooled (PPL) placebo. 
a)  b)  
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Solid lines indicate achievement of a significant difference from placebo in hierarchal testing; dashed lines indicate statistical significance was 
not reached. The alpha level for all end-points was 0.049 for the 14-days arms and 0.001 for the 28-days arms. The confidence interval is 
95.1% for comparisons of Ciprofloxacin DPI 14-days on/off versus placebo and 99.9% for comparisons of Ciprofloxacin DPI 28-days on/off 
versus placebo CI: confidence interval; DPI: dry powder for inhalation; EMA: European Medicines Agency; EOT: end of treatment; FDA: Food 
and Drug Administration; FEV1: forced expiratory volume in 1 second; HR: hazard ratio; IRR: incidence rate ratio; MPL: matched placebo; OR: 
odds ratio; PPL: pooled placebo; QOL-B RSS: Quality of Life-Bronchiectasis Respiratory Symptom Domain Score; SGRQ: St. George’s 
Respiratory Questionnaire. #: for the primary end-points, an exacerbation (stringent definition) was defined as a respiratory event requiring 
systemic antibiotic use AND presence of fever (>38.0°C) or malaise/fatigue AND worsening of at least three of five signs/symptoms (dyspnoea, 
wheezing, cough, 24-hour sputum volume or sputum purulence). †: the less stringent definition of exacerbation used in the indicated secondary 
end-points was a respiratory event with systemic antibiotic use AND worsening of at least one sign/symptom. ‡: pre-specified pathogens were: 
P. aeruginosa, H. influenzae, M. catarrhalis, S. aureus, S. pneumoniae, S. maltophilia, and B. cepacia. Eradication of pathogens was defined 
as a negative culture result at end of therapy for all pre-specified pathogens in subjects with a positive post-baseline culture for at least one pre-
specified pathogen. Occurrence of a new pathogen was defined as a positive culture for at least one pre-specified pathogen at end of therapy 
in subject who did not have a positive culture for that pathogen at the start of treatment. 
 
